Barinthus Biotherapeutics (BRNS) Cash from Investing Activities (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Cash from Investing Activities of $55000.0 for Q1 2026, up 1200.0% on a YoY basis from $4230.8 in Q1 2025, and up 2650.0% quarter-over-quarter from $2000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at $55000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 1200.0% year-over-year to $55000.0; the trailing twelve-month figure through Mar 2026 stood at $476000.0 (up 180.81% YoY), and the FY2025 full-year result was $416000.0, up 146.64% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $55000.0, up from $2000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $451000.0 in Q3 2025, with the low at -$3.0 million in Q2 2023.
- Historically, Cash from Investing Activities has averaged -$681411.8 across 5 years, with a median of -$192000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 1476.56% — and 2026, when it soared 1200.0%.
- Barinthus Biotherapeutics' Cash from Investing Activities stood at -$586000.0 in 2022, then jumped by 126.11% to $153000.0 in 2023, then sank by 281.7% to -$278000.0 in 2024, then soared by 100.72% to $2000.0 in 2025, then surged by 2650.0% to $55000.0 in 2026.
- The last three Cash from Investing Activities figures came in at $55000.0 (Q1 2026), $2000.0 (Q4 2025), and $451000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Barinthus Biotherapeutics | 27.57 Mn | -39.54 Mn | - | 55,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55,000.00 |
| Mar 31, 2026 | 55,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 451,000.00 |
| Sep 30, 2025 | 451,000.00 |
| Jun 30, 2025 | -32,000.00 |
| Jun 30, 2025 | -32,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | -278,000.00 |
| Dec 31, 2024 | -278,000.00 |
| Sep 30, 2024 | -114,000.00 |
| Sep 30, 2024 | -114,000.00 |
| Jun 30, 2024 | -192,000.00 |
| Jun 30, 2024 | -192,000.00 |
| Mar 31, 2024 | -308,000.00 |
| Mar 31, 2024 | -308,000.00 |
| Dec 31, 2023 | 153,000.00 |
| Dec 31, 2023 | 153,000.00 |